Market capitalization | $0.00 |
Enterprise Value | $1.24m |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 0.20 |
P/S ratio (TTM) P/S ratio | 0.00 |
Short interest | 0.12% |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
1 Analyst has issued a forecast HTG Molecular Diagnostics, Inc.:
1 Analyst has issued a forecast HTG Molecular Diagnostics, Inc.:
Dec '22 |
+/-
%
|
||
Revenue | 6.37 6.37 |
29%
29%
|
|
Gross Profit | 1.79 1.79 |
63%
63%
|
|
EBITDA | -20 -20 |
16%
16%
|
EBIT (Operating Income) EBIT | -21 -21 |
14%
14%
|
Net Profit | -22 -22 |
26%
26%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It offers instruments, reagents and services for molecular profiling applications. The firm serves biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
Head office | United States |
CEO | John Lubniewski |
Founded | 1997 |
Website | www.htgmolecular.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.